Skip to main content
. 2011 Jun 13;118(5):1350–1358. doi: 10.1182/blood-2011-03-345272

Table 1.

Summary of profiled DLBCL cohorts

Study cohort DLBCL1 (training) DLBCL2 (test) DLBCL3 (test) DLBCL4 (validation)
No. of patients 233 181 131 147
Specimen type Frozen Frozen Frozen FFPE
Study group Multinational LLMPP Multinational LLMPP Multinational MMMLNP Multinational
Therapy regimen R-CHOP CHOP CHOP R-CHOP
End point(s) and covariates OS, IPI, COO OS, IPI, COO OS PFS, OS, IPI
Median age, y (range) 62 (17-92) 65 (14-88) 67 (8-93) 57 (16-92)
IPI distribution, n (%)
    Low [0,1] 75 (32) 62 (34) N/A 56 (38)
    Low int. [2] 43 (18) 45 (25) 35 (24)
    High int. [3] 30 (13) 30 (17) 37 (25)
    High [4,5] 24 (10) 23 (13) 19 (13)
COO, n (%)
    ABC-like 93 (40) 74 (41) 50 (38) N/A
    GCB-like 107 (46) 76 (42) 47 (36)
    Unclassified 33 (14) 31 (17) 34 (26)
Measurement platform Affymetrix HG-U133 Plus 2.0 Affymetrix HG-U133 Plus 2.0 Affymetrix HG-U133A ABI 7900HT TaqMan RT-PCR
Primary data source NCBI GSE10846 NCBI GSE10846 NCBI GSE4475 Present study
LMO2 probe set 4005_at 4005_at 4005_at Hs00277106_m1
TNFRSF9 probe set 3604_at 3604_at 3604_at Hs00155512_m1
Reference Lenz et al, 200818 Lenz et al, 200818Rosenwald et al, 200211 Hummel et al, 200612 98 samples from Malumbres et al, 200819

LLMPP indicates Leukemia/Lymphoma Molecular Profiling Project; MMMLNP, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe; COO, cell-of-origin classification; NCBI, National Center for Biotechnology Information; and GSE, Gene Expression Omnibus series.